Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Impatto del sesso su tossicità ed efficacia delle terapie antitumorali in pazienti trattati per sarcoma presso un Centro di riferimento – SEx Differences In Toxicity and Outcomes in patients treated for Sarcoma in a reference center (SEDITOS)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
SEDITOS
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Esiti funzionali e risultati qualitativi dopo resezione anteriore di retto mininvasiva con preservazione sfinteriale: esperienza monocentrica di sei anni di attività

Stato
Aperto - reclutamento in corso
Codice studio
LARS-CRC-2024
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Principal Investigator

Studio di fase II su pembrolizumab in combinazione con cisplatino o carboplatino e pemetrexed come chemio+immunoterapia di induzione nel mesotelioma pleurico epitelioide e bifasico resecabile (studio CHIMERA)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
IOV-Me-01-2023-CHIMERA
Codice EudraCT
2023-509584-24-00
Sponsor/Promotore
IOV
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Regorafenib in pazienti con recidiva di meningioma grado 2 e 3: studio randomizzato, multicentrico di fase 2 (MIRAGE trial)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
IOV-BT-1-2023 MIRAGE
Codice EudraCT
2024-510954-28
Sponsor/Promotore
IOV
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
JZP598-303 (EmpowHER 303)
Codice EudraCT
2023-508960-31-00
Sponsor/Promotore
Jazz Pharmaceuticals Ireland Limited
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Landscape clinica e biologica del carcinoma mammario nelle minoranze di genere (uomini e popolazione transgender e gender diverse): uno studio osservazionale – studio homBREast

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
IOV-2024- homBREast
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top